Cel
Key Metrics
Market Snapshot
About
CEL-SCI Corporation (CVM) is a clinical-stage biotechnology company headquartered in Vienna, Virginia, focused on developing immunotherapies designed to harness the body's immune system to fight cancer and other diseases.
The company's lead investigational drug is Multikine (Leukocyte Interleukin, Injection), a complex immunotherapy that has completed a Phase III clinical trial. This pivotal study evaluated Multikine for the potential treatment of certain newly diagnosed head and neck cancers. In addition to Multikine, CEL-SCI is advancing its proprietary LEAPS technology platform. This patented approach is a T-cell modulation process intended to direct the immune system's response. The company is exploring LEAPS-based product candidates for a broad range of conditions including infectious diseases, autoimmune disorders, and cancer. For example, several preclinical candidates such as CEL-2000, CEL-4000, and CEL-5000 are in development as potential therapeutic treatments for rheumatoid arthritis.
CEL-SCI operates primarily as a research and development organization. The company formed a strategic partnership with the Saudi Arabian Pharma Company related to the development of Multikine for head and neck cancer. CEL-SCI was incorporated in 1983 and continues to pursue regulatory pathways for its lead candidate based on its Phase III trial data while furthering earlier-stage research from its LEAPS platform.